12-15 May 2019
- Isabela Ribeiro, Head of Dynamic Portfolio Unit – presentation on clinical trials for Chagas disease
- Nick White, Chair DNDi SAC – presentation on the global situation in infectious diseases & drug discovery for infectious diseases
In Africa, results of a Phase III study on HIV/VL in Ethiopia showed high efficacy of a new combination therapy for co-infected patients, a Phase III study began to test new combination treatment for visceral leishmaniasis, and a Phase II study testing new treatments for PKDL started in Sudan. In Asia, the results of an infectivity study in Bangladesh confirmed that PKDL acts as a reservoir for leishmaniasis infection, with implications for elimination efforts across South Asia. In Latin America, the Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.
A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.
Two Phase I studies in healthy volunteers for potentially macrofilaricidal drugs were successfully completed, for emodepside (Bayer) and the antibiotic TylAMac (AbbVie). Phase II studies are planned for sub-Saharan Africa.
Health Policy Watch [5 February 2019]
“New funding partnership to develop innovative drugs for leishmaniasis”
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
20-23 February 2019
- Presentation of the development of DNDI-0690, a new clinical candidate for visceral leishmaniasis
20-22 February 2019
- Presentation of a poster on drug discovery for leishmaniasis (Open Synthesis Project)
Science & Enterprise [30 January 2019]
“Compounds made available for pandemic drug discovery”
Chemical & Engineering News [29 January 2019]
“Open-source drug discovery takes aim at malaria and neglected diseases”
Pharmaceutical Technology [29 January 2019]
“MMV and DNDi create a response box to foster R&D for pandemic diseases”
IP Watch [29 January 2019]
“DNDi, MMV make 400 compounds available to boost pandemic disease research”
Geneva – 29 January 2019
Pandemic Response Box harnesses open and collaborative approaches to medical innovation
Medicines for Malaria Venture (MMV) and DNDi have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases.
21st Century Drug Discovery and Development for Global Health
17-20 October 2018
- Nathalie Strub-Wourgaft, NTD Director – presentation on the new therapies for sleeping sickness
- Charles Mowbray, Discovery Director – presentation on new orally active treatments for leishmaniasis
Jornal da USP [20 June 2018]
“Evento traz novas tecnologias aplicadas na descoberta de medicamentos” – “Event overviews new technologies used in drug discovery”
2-4 October 2018
- Marion Laumonier, Head of Regulatory Affairs – presentation on registration pathways and forum discussion on collaborative efforts between regulators and stakeholders
by Lim W, Melse Y, Konings M, Phat Duong H, Eadie K, Laleu B, Perry B, Todd M, Ioset J-R, and van de Sande W.
PLOS Neglected Tropical Diseases, April 2018
7 September 2018
Poster presentation of an Open Synthesis Network project for leishmaniasis drug discovery
26-31 August 2018
Poster on the mechanism of action of an experimental drug against Chagas disease